Glycophos

Glycophos is a prescription sodium glycerophosphate pentahydrate solution for injection. It contains the active ingredient sodium glycerophosphate pentahydrate in a sterile aqueous form for intravenous administration. Marketed in the European Union, Glycophos provides phosphate and sodium ions to support metabolic processes and electrolyte balance. The product is supplied as a ready‑to‑use injectable solution. It is intended for use under medical supervision and is stored according to manufacturer guidelines.

Glycophos is used as an intravenous phosphate supplement in clinical settings where rapid replenishment of phosphate and sodium is required, particularly when oral supplementation is not feasible.

- Correction of hypophosphatemia in hospitalized patients - Support during parenteral nutrition - Management of electrolyte disturbances associated with renal replacement therapy - Adjunct in cardiac surgery to maintain phosphate levels - Use in patients with severe burns or trauma to restore phosphate balance

Potential adverse effects of Glycophos may arise from its phosphate and sodium content or from infusion‑related reactions.

Common: - Mild hyperphosphatemia - Transient hypernatremia - Injection site pain or erythema - Nausea - Headache

Serious: - Severe hyperphosphatemia leading to calcium‑phosphate precipitation - Acute renal failure exacerbation - Severe electrolyte imbalance causing cardiac arrhythmia - Anaphylactic reaction to the solution

When prescribing Glycophos, clinicians should consider several precautions to minimize risk and ensure appropriate use.

- Assess baseline serum phosphate, calcium, and sodium levels before administration - Avoid use in patients with severe hyperphosphatemia or hypercalcemia - Monitor renal function, especially in those with impaired clearance - Adjust infusion rate in patients at risk for fluid overload - Observe for signs of electrolyte imbalance during and after infusion - Use caution in patients with cardiac disease or hypertension

Glycophos may interact with other medications or solutions administered intravenously, requiring attention to compatibility and cumulative electrolyte effects.

Avoid: - Concurrent infusion of calcium‑containing solutions that may precipitate calcium phosphate - Co‑administration with other phosphate salts that could cause excessive phosphate load

Use with caution: - Loop diuretics that alter sodium balance - ACE inhibitors or ARBs that affect renal handling of electrolytes - Medications that prolong QT interval, as electrolyte shifts may increase risk - Blood products containing citrate, which can bind calcium